PRRT — peptide receptor radionuclide therapy — is the radioligand-peptide approach that uses tumor-targeting peptides linked to therapeutic radioisotopes. Lutathera (Lu-177 dotatate) for SSTR2-positive neuroendocrine tumors set the commercial template; Pluvicto (Lu-177-PSMA) for prostate cancer expanded it.
Coverage on this site spans alpha-emitter PRRT (212Pb-based programs from Perspective Therapeutics, Crinetics' programs), the broader SSTR-pan and SSTR2-selective candidates, and academic work on novel radionuclide-peptide pairings. Imaging-paired PRRT (Gallium-68 PET, AlphaGen) is part of the same diagnostic-therapeutic pipeline.
Stories here cover trial readouts, real-world data, and the radioligand-peptide market. See #lutathera, #sstr2, #radioligand, and #radioligand-therapy.
University of California, San Francisco researchers reported in Clinical Cancer Research on October 21, 2026 a single-arm pilot of the PD-1 inhibitor pembrolizumab given with 177Lu-DOTATATE (Lutathera), a radioactive somatostatin-analog peptide, in 26 adults with grade 2 or 3 well-differentiated metastatic neuroendocrine tumors and a Ki-67 index above 10%, 20 of them grade 3. The objective response rate was 35%, median progression-free survival 13.3 months, and median overall survival 24.1 months, while severe adverse events occurred in 14 patients (54%). The authors concluded that the added benefit of the immunotherapy remains unclear and that the severe side-effect rate was higher than expected for Lutathera alone.
Lantheus's PNT2003 (lutetium Lu 177 dotatate ANDA-route radioequivalent) is positioned to enter its final FDA approval window after the 30-month regulatory stay expires in June 2026. The product would be the second SSTR2 PRRT in the US neuroendocrine tumor market alongside Novartis's Lutathera, which has held the category since 2018. The regulatory framework: PNT2003 received tentative approval March 2; PYLARIFY TruVu (piflufolastat F 18) high-throughput PSMA PET formulation approved March 6. ITM's Lu-edotreotide-177 (ITM-11) follows on a separate August 28, 2026 PDUFA, and Crinetics' CRN09682 SSTR2 non-peptide drug conjugate is in Phase 1/2 BRAVESST2 — making 2026 a defining year for the SSTR2 PRRT competitive frame.
ITM Isotope Technologies Munich's Lu-edotreotide-177 (branded ITM-11), a peptide radioligand therapy targeting somatostatin receptor 2 (SSTR2) in gastroenteropancreatic neuroendocrine tumors, has an FDA decision goal of August 28, 2026. If approved, ITM-11 would expand US PRRT options beyond Novartis's Lutathera, which has held the SSTR2 PRRT category since 2018. Companion radiopharmaceutical kit Ga 68 edotreotide (LNTH-2501) supports PET imaging for SSTR-positive NETs. The August PDUFA sits alongside the July 23–24 PCAC meeting on seven 503A peptides and Roche's mid-2026 enicepatide+petrelintide combination Phase 2 start as the next-quarter peptide regulatory inflection points.
A Journal of Nuclear Medicine study analyzed patterns of progression in 195 patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE PRRT. Progression occurred in 107 patients (54.9%), most often in the liver (60.7%) followed by bone (25.3%). Post-progression somatostatin receptor PET imaging showed retained SSTR uptake in 59.7% of patients, increased uptake in 18.2%, and reduced uptake in 19.5%, indicating that the majority remain candidates for additional SSTR-targeted radioligand therapy. The dataset reinforces the clinical case for sequencing peptide radioligand therapies rather than abandoning the modality at first progression.
Perspective Therapeutics' [212Pb]VMT-α-NET, a first-in-class alpha-emitter peptide radionuclide therapy targeting SSTR2, achieved objective responses in 10 of 23 (43%) Cohort 2 patients with metastatic neuroendocrine tumors in Phase 1/2a data presented at AACR 2026. 18 of 25 patients (72%) remained alive without progression; no dose-limiting toxicities or Grade 4/5 adverse events observed.
Novigenix presented first human clinical data at AACR 2026 from its LITOSeek AI-enabled liquid biopsy platform showing dynamic immune-transcriptomic responses in metastatic GEP-NET patients treated with either [212Pb]DOTAMTATE (AlphaMedix) alpha-emitter PRRT or [177Lu]DOTATATE (Lutathera) beta-emitter PRRT. The platform may enable treatment stratification between alpha- and beta-emitter radionuclide therapies.
A DelveInsight market analysis published April 20 projects 7.3% CAGR growth in the pheochromocytoma and paraganglioma treatment market through 2036, driven by SSTR2 analogs and peptide receptor radionuclide therapies including Novartis's Lutathera (lutetium-177 dotatate). PRRT remains one of the few FDA-approved peptide therapeutics for rare neuroendocrine tumors, binding SSTR2 to deliver targeted radiation.